protein tyrosine phosphatase non-receptor type 20C, pseudogeneGenealiases: PTPN20C · bA164N7.3
Q-omics provides the consensus-scored PTPN20CP profile across patient tissues and cancer cell-line models. PTPN20CP expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, PTPN20CP is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, PTPN20CP RNA expression shows 10,016 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight READ, UCEC, and PCPG as cancer lineages where PTPN20CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN20CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN20CP survival associations across molecular data types. PTPN20CP RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN20CP RNA expression–survival associations across cancer types. High PTPN20CP expression shows unfavorable associations in READ, CHOL, MESO, KICH, ACC and COAD. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify READ as the clearest survival context for PTPN20CP RNA expression.
This table summarizes PTPN20CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for PTPN20CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN20CP shows lower tumor expression in UCEC, KIRP, THCA and ESCA and higher tumor expression in CHOL. The UCEC box plot shows higher PTPN20CP RNA expression in normal versus tumor tissue (log2 FC = −0.133, t-test p = .022).
This table shows molecular features associated with PTPN20CP in patient tissues and cancer cell lines. In patient samples, PTPN20CP shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
